Trevi Therapeutics, Inc. TRVI Operating lease right-of-use assets amortization expense
Operating lease right-of-use assets amortization expense at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s operating lease right-of-use assets amortization expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s operating lease right-of-use assets amortization expense?
- Trevi Therapeutics, Inc. (TRVI) reported operating lease right-of-use assets amortization expense of $105K in Q1 2026.
- How has Trevi Therapeutics, Inc.'s operating lease right-of-use assets amortization expense changed year-over-year?
- Trevi Therapeutics, Inc.'s operating lease right-of-use assets amortization expense decreased by 6.3% year-over-year, from $112K to $105K.
- What does operating lease right-of-use assets amortization expense mean?
- The periodic expense recognized for the consumption of the economic benefits of right-of-use assets related to operating leases. This reflects the systematic allocation of the asset's cost over the lease term. It is a standard accounting measure for companies with significant leased office or laboratory space.